Marinos Dalakas

TitleProfessor
InstitutionThomas Jefferson University
DepartmentNeurology
Address900 Walnut Street
Philadelphia PA 19107
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Oaklander AL, Mills AJ, Kelley M, Toran LS, Smith B, Dalakas MC, Nath A. Peripheral Neuropathy Evaluations of Patients With Prolonged Long COVID. Neurol Neuroimmunol Neuroinflamm. 2022 05; 9(3). PMID: 35232750.
      Citations:    
    2. Stathopoulos P, Dalakas MC. Evolution of Anti-B Cell Therapeutics in Autoimmune Neurological Diseases. Neurotherapeutics. 2022 Feb 18. PMID: 35182380.
      Citations:    
    3. Dalakas MC. Stiff-person Syndrome and GAD Antibody-spectrum Disorders: GABAergic Neuronal Excitability, Immunopathogenesis and Update on Antibody Therapies. Neurotherapeutics. 2022 Jan 27. PMID: 35084720.
      Citations:    
    4. Dalakas MC. Unconvincing Evidence of SARS-CoV-2-Associated Myositis in Autopsied Muscles. JAMA Neurol. 2022 01 01; 79(1):92. PMID: 34807230.
      Citations:    
    5. Dalakas MC. IgG4-Mediated Neurologic Autoimmunities: Understanding the Pathogenicity of IgG4, Ineffectiveness of IVIg, and Long-Lasting Benefits of Anti-B Cell Therapies. Neurol Neuroimmunol Neuroinflamm. 2022 01; 9(1). PMID: 34845096.
      Citations:    
    6. Dalakas MC. Update on Intravenous Immunoglobulin in Neurology: Modulating Neuro-autoimmunity, Evolving Factors on Efficacy and Dosing and Challenges on Stopping Chronic IVIg Therapy. Neurotherapeutics. 2021 10; 18(4):2397-2418. PMID: 34766257.
      Citations:    
    7. Gontika M, Skarlis C, Markoglou N, Evangelopoulos ME, Velonakis G, Chrousos GP, Dalakas M, Stefanis L, Anagnostouli M. Fingolimod as a first- or second-line treatment in a mini-series of young Hellenic patients with adolescent-onset multiple sclerosis: focus on immunological data. Neurol Sci. 2021 Oct 01. PMID: 34596776.
      Citations:    
    8. Stathopoulos P, Dalakas MC. Autoimmune Neurogenic Dysphagia. Dysphagia. 2021 Jul 05. PMID: 34226958.
      Citations:    
    9. Anagnostouli MC, Velonakis G, Dalakas MC. Aggressive Herpes Zoster in Young Patients With Multiple Sclerosis Under Dimethyl Fumarate: Significance of CD8+ and Natural Killer Cells. Neurol Neuroimmunol Neuroinflamm. 2021 07; 8(4). PMID: 34049996.
      Citations:    
    10. Tsiortou P, Alexopoulos H, Dalakas MC. GAD antibody-spectrum disorders: progress in clinical phenotypes, immunopathogenesis and therapeutic interventions. Ther Adv Neurol Disord. 2021; 14:17562864211003486. PMID: 33854562.
      Citations:    
    11. Dalakas MC, Spaeth PJ. The importance of FcRn in neuro-immunotherapies: From IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors. Ther Adv Neurol Disord. 2021; 14:1756286421997381. PMID: 33717213.
      Citations:    
    12. Dalakas MC, Bitzogli K, Alexopoulos H. Anti-SARS-CoV-2 Antibodies Within IVIg Preparations: Cross-Reactivities With Seasonal Coronaviruses, Natural Autoimmunity, and Therapeutic Implications. Front Immunol. 2021; 12:627285. PMID: 33679770.
      Citations:    
    13. Dalmau J, Dalakas MC, Kolson DL, Paul F, Zamvil SS. N2 year in review. Neurol Neuroimmunol Neuroinflamm. 2021 Jan; 8(1). PMID: 33411673.
      Citations:    
    14. Dalakas MC. A HSCT TRIAL IN STIFF PERSON SYNDROME: LIMITED BENEFITS HALT ENROLLMENT BUT SHOULD BE MORE TO COME? Neurology. 2020 Dec 14. PMID: 33318165.
      Citations:    
    15. Dalakas MC. Inflammatory myopathies: update on diagnosis, pathogenesis and therapies, and COVID-19-related implications. Acta Myol. 2020 Dec; 39(4):289-301. PMID: 33458584.
      Citations:    
    16. Vlachoyiannopoulos P, Alexopoulos H, Apostolidi I, Bitzogli K, Barba C, Athanasopoulou E, Dalakas M, Tzioufas A. Anti-SARS-CoV-2 antibody detection in healthcare workers of two tertiary hospitals in Athens, Greece. Clin Immunol. 2020 12; 221:108619. PMID: 33127563.
      Citations:    
    17. Virupakshaiah A, Dalakas MC, Desai N, Mintzer S, Ratliff J. LGI1 encephalitis with squamous lung-cell carcinoma: Resolution after tumor resection. Neurol Neuroimmunol Neuroinflamm. 2021 Jan; 8(1). PMID: 33037051.
      Citations:    
    18. Dalakas MC. Progress in the therapy of myasthenia gravis: getting closer to effective targeted immunotherapies. Curr Opin Neurol. 2020 Oct; 33(5):545-552. PMID: 32833750.
      Citations:    
    19. Dalakas MC, Alexopoulos H, Spaeth PJ. Complement in neurological disorders and emerging complement-targeted therapeutics. Nat Rev Neurol. 2020 Nov; 16(11):601-617. PMID: 33005040.
      Citations:    
    20. Alexopoulos H, Magira E, Bitzogli K, Kafasi N, Vlachoyiannopoulos P, Tzioufas A, Kotanidou A, Dalakas MC. Anti-SARS-CoV-2 antibodies in the CSF, blood-brain barrier dysfunction, and neurological outcome: Studies in 8 stuporous and comatose patients. Neurol Neuroimmunol Neuroinflamm. 2020 11; 7(6). PMID: 32978291.
      Citations:    
    21. Dalakas MC. Guillain-Barré syndrome: The first documented COVID-19-triggered autoimmune neurologic disease: More to come with myositis in the offing. Neurol Neuroimmunol Neuroinflamm. 2020 09; 7(5). PMID: 32518172.
      Citations:    
    22. Costello F, Dalakas MC. Cranial Neuropathies and COVID-19: Neurotropism and Autoimmunity. Neurology. 2020 Jun 02. PMID: 32487714.
      Citations:    
    23. Gontika M, Skarlis C, Artemiadis A, Pons R, Mastroyianni S, Vartzelis G, Theodorou V, Kilindireas K, Stefanis L, Dalakas M, Chrousos G, Anagnostouli M. HLA-DRB1 allele impact on pediatric multiple sclerosis in a Hellenic cohort. Mult Scler J Exp Transl Clin. 2020 Jan-Mar; 6(1):2055217320908046. PMID: 32133149.
      Citations:    
    24. Dalmau J, Dalakas MC, Kolson DL, Paul F, Zamvil SS. N2 year in review. Neurol Neuroimmunol Neuroinflamm. 2020 Jan; 7(1). PMID: 31831570.
      Citations:    
    25. Dimitriadou MM, Alexopoulos H, Akrivou S, Gola E, Dalakas MC. Anti-Neuronal Antibodies Within the IVIg Preparations: Importance in Clinical Practice. Neurotherapeutics. 2019 Oct 31. PMID: 31673865.
      Citations:    
    26. Dalakas MC. Case 22-2019: A 65-Year-Old Woman with Myopathy. N Engl J Med. 2019 10 24; 381(17):1693. PMID: 31644862.
      Citations:    
    27. Alexopoulos H, Dalakas MC. The immunobiology of autoimmune encephalitides. J Autoimmun. 2019 Nov; 104:102339. PMID: 31611142.
      Citations:    
    28. Kosmidis ML, Pikazis D, Vlachoyiannopoulos P, Tzioufas AG, Dalakas MC. Trial of canakinumab, an IL-1ß receptor antagonist, in patients with inclusion body myositis. Neurol Neuroimmunol Neuroinflamm. 2019 Jul; 6(4):e581. PMID: 31355317.
      Citations:    
    29. Keller CW, Quast I, Dalakas MC, Lünemann JD. IVIG efficacy in CIDP patients is not associated with terminal complement inhibition. J Neuroimmunol. 2019 Feb 10; 330:23-27. PMID: 30772754.
      Citations:    
    30. Dalakas MC. Immunotherapy in myasthenia gravis in the era of biologics. Nat Rev Neurol. 2019 Feb; 15(2):113-124. PMID: 30573759.
      Citations:    
    31. Rakocevic G, Alexopoulos H, Dalakas MC. Quantitative clinical and autoimmune assessments in stiff person syndrome: evidence for a progressive disorder. BMC Neurol. 2019 Jan 03; 19(1):1. PMID: 30606131.
      Citations:    
    32. Dalakas MC. Neurological complications of immune checkpoint inhibitors: what happens when you 'take the brakes off' the immune system. Ther Adv Neurol Disord. 2018; 11:1756286418799864. PMID: 30245744.
      Citations:    
    33. Hughes R, Dalakas MC, Merkies I, Latov N, Léger JM, Nobile-Orazio E, Sobue G, Genge A, Cornblath D, Merschhemke M, Ervin CM, Agoropoulou C, Hartung HP. Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial. Lancet Neurol. 2018 Aug; 17(8):689-698. PMID: 30001923.
      Citations:    
    34. Alexopoulos H, Akrivou S, Mastroyanni S, Antonopoulou M, Dinopoulos A, Giorgi M, Konstantinou K, Kouremenos E, Lariou M, Naoumis D, Pavlidou E, Pavlou E, Voudris K, Vlachoyiannopoulos P, Dalakas MC. Postherpes simplex encephalitis: a case series of viral-triggered autoimmunity, synaptic autoantibodies and response to therapy. Ther Adv Neurol Disord. 2018; 11:1756286418768778. PMID: 29774053.
      Citations:    
    35. Dalakas MC. Myositis: Are autoantibodies pathogenic in necrotizing myopathy? Nat Rev Rheumatol. 2018 May; 14(5):251-252. PMID: 29651118.
      Citations:    
    36. Rakocevic G, Martinez-Outschoorn U, Dalakas MC. Obinutuzumab, a potent anti-B-cell agent, for rituximab-unresponsive IgM anti-MAG neuropathy. Neurol Neuroimmunol Neuroinflamm. 2018 Jul; 5(4):e460. PMID: 29629397.
      Citations:    
    37. Dalakas MC. Advances in the diagnosis, immunopathogenesis and therapies of IgM-anti-MAG antibody-mediated neuropathies. Ther Adv Neurol Disord. 2018; 11:1756285617746640. PMID: 29403542.
      Citations:    
    38. Dalakas MC. Subcutaneous IgG for chronic inflammatory demyelinating polyneuropathy. Lancet Neurol. 2018 Jan; 17(1):20-21. PMID: 29122522.
      Citations:    
    39. Dalakas MC, Rakocevic G, Dambrosia JM, Alexopoulos H, McElroy B. A double-blind, placebo-controlled study of rituximab in patients with stiff person syndrome. Ann Neurol. 2017 Jul 27. PMID: 28749549.
      Citations:    
    40. Dalakas MC. Gene therapy for Duchenne muscular dystrophy: balancing good science, marginal efficacy, high emotions and excessive cost. Ther Adv Neurol Disord. 2017 Aug; 10(8):293-296. PMID: 28781610.
      Citations:    
    41. Dalakas MC. Rituximab in anti-MAG neuropathy: More evidence for efficacy and more predictive factors. J Neurol Sci. 2017 Jun 15; 377:224-226. PMID: 28477700.
      Citations:    
    42. Fouka P, Alexopoulos H, Chatzi I, Dedos SG, Samiotaki M, Panayotou G, Politis P, Tzioufas A, Dalakas MC. Antibodies to inositol 1,4,5-triphosphate receptor 1 in patients with cerebellar disease. Neurol Neuroimmunol Neuroinflamm. 2017 Jan; 4(1):e306. PMID: 27957507.
      Citations:    
    43. Dalakas MC. Treating myasthenia on consensus guide: Helpful and challenging but still unfinished business. Neurology. 2016 Jul 26; 87(4):350-1. PMID: 27358340.
      Citations:    
    44. Dalakas MC. Necrotising autoimmune myopathy (NAM): antibodies seem to be specific markers in aiding diagnosis. J Neurol Neurosurg Psychiatry. 2016 Oct; 87(10):1037. PMID: 27151962.
      Citations:    
    45. Schmidt K, Kleinschnitz K, Rakocevic G, Dalakas MC, Schmidt J. Molecular treatment effects of alemtuzumab in skeletal muscles of patients with IBM. BMC Neurol. 2016; 16(1):48. PMID: 27083892.
      Citations:    
    46. Dalakas MC, Gooch C. Close to the node but far enough: What nodal antibodies tell us about CIDP and its therapies. Neurology. 2016 Mar 1; 86(9):796-7. PMID: 26843563.
      Citations:    
    47. Alexopoulos H, Biba A, Dalakas MC. Anti-B-Cell Therapies in Autoimmune Neurological Diseases: Rationale and Efficacy Trials. Neurotherapeutics. 2016 Jan; 13(1):20-33. PMID: 26566961.
      Citations:    
    48. Kampylafka EI, Alexopoulos H, Dalakas MC, Tzioufas AG. Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity. Neurotherapeutics. 2016 Jan; 13(1):163-78. PMID: 26510559.
      Citations:    
    49. Dalakas MC. Neuro-Immunotherapies: A 30-year Retrospective of an Overwhelming Success and a Brighter Future. Neurotherapeutics. 2016 Jan; 13(1):1-3. PMID: 26684870.
      Citations:    
    50. Magira EE, Alexopoulos H, Charitatos E, Michas D, Dalakas MC. Progressive encephalomyelitis with rigidity and myoclonus (PERM): brucellosis as a possible triggering factor and long-term follow-up therapy with rituximab. Ther Adv Neurol Disord. 2016 Jan; 9(1):69-73. PMID: 26788132.
      Citations:    
    51. Lünemann JD, Quast I, Dalakas MC. Efficacy of Intravenous Immunoglobulin in Neurological Diseases. Neurotherapeutics. 2016 Jan; 13(1):34-46. PMID: 26400261.
      Citations:    
    52. Dalakas MC, Schmidt J. Viruses in IBM: Hit-and-run, hide and persist, or irrelevant? Neurology. 2016 Jan 19; 86(3):204-5. PMID: 26683647.
      Citations:    
    53. Dalakas MC. Future perspectives in target-specific immunotherapies of myasthenia gravis. Ther Adv Neurol Disord. 2015 Nov; 8(6):316-27. PMID: 26600875.
      Citations:    
    54. Alexopoulos H, Kampylafka EI, Fouka P, Tatouli I, Akrivou S, Politis PK, Moutsopoulos HM, Tzioufas AG, Dalakas MC. Anti-aquaporin-4 autoantibodies in systemic lupus erythematosus persist for years and induce astrocytic cytotoxicity but not CNS disease. J Neuroimmunol. 2015 Dec 15; 289:8-11. PMID: 26616866.
      Citations:    
    55. Quast I, Keller CW, Maurer MA, Giddens JP, Tackenberg B, Wang LX, Münz C, Nimmerjahn F, Dalakas MC, Lünemann JD. Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity. J Clin Invest. 2015 Nov 2; 125(11):4160-70. PMID: 26436649.
      Citations:    
    56. Kampylafka EI, Alexopoulos H, El Hamidieh A, Dalakas MC, Andreakos E, Tzioufas AG. Immunization of mice with a peptide derived from the HTLV-1 TAX1BP1 protein induces cross-reactive antibodies against aquaporin 4. Autoimmunity. 2015 Nov; 48(7):453-9. PMID: 26287441.
      Citations:    
    57. Chin RL, Deng C, Bril V, Hartung HP, Merkies IS, Donofrio PD, Van Doorn PA, Dalakas MC, Latov N. Follow-up nerve conduction studies in CIDP after treatment with IGIV-C: Comparison of patients with and without subsequent relapse. Muscle Nerve. 2015 Oct; 52(4):498-502. PMID: 25728021.
      Citations:    
    58. Dalakas MC. Inflammatory Muscle Diseases. N Engl J Med. 2015 Jul 23; 373(4):393-4. PMID: 26200989.
      Citations:    
    59. Chalmoukou K, Alexopoulos H, Akrivou S, Stathopoulos P, Reindl M, Dalakas MC. Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis. Neurol Neuroimmunol Neuroinflamm. 2015 Aug; 2(4):e131. PMID: 26185777.
      Citations:    
    60. Muth IE, Zschüntzsch J, Kleinschnitz K, Wrede A, Gerhardt E, Balcarek P, Schreiber-Katz O, Zierz S, Dalakas MC, Voll RE, Schmidt J. HMGB1 and RAGE in skeletal muscle inflammation: Implications for protein accumulation in inclusion body myositis. Exp Neurol. 2015 Sep; 271:189-97. PMID: 26048613.
      Citations:    
    61. Dalakas MC. Inflammatory muscle diseases. N Engl J Med. 2015 Apr 30; 372(18):1734-47. PMID: 25923553.
      Citations:    
    62. Harris-Love MO, Joe G, Davenport TE, Koziol D, Abbett Rose K, Shrader JA, Vasconcelos OM, McElroy B, Dalakas MC. Reliability of the adult myopathy assessment tool in individuals with myositis. Arthritis Care Res (Hoboken). 2015 Apr; 67(4):563-70. PMID: 25201624.
      Citations:    
    63. Stathopoulos P, Alexopoulos H, Dalakas MC. Autoimmune antigenic targets at the node of Ranvier in demyelinating disorders. Nat Rev Neurol. 2015 Mar; 11(3):143-56. PMID: 25623793.
      Citations:    
    64. Lünemann JD, Nimmerjahn F, Dalakas MC. Intravenous immunoglobulin in neurology--mode of action and clinical efficacy. Nat Rev Neurol. 2015 Feb; 11(2):80-9. PMID: 25561275.
      Citations:    
    65. Davenport TE, Benson K, Baker S, Gracey C, Rakocevic G, McElroy B, Dalakas M, Shrader JA, Harris-Love MO. Lower extremity peak force and gait kinematics in individuals with inclusion body myositis. Arthritis Care Res (Hoboken). 2015 Jan; 67(1):94-101. PMID: 25201017.
      Citations:    
    66. Alexopoulos H, Dagklis IE, Akrivou S, Bostantjopoulou S, Dalakas MC. Autoimmune encephalitis with GABAB antibodies, thymoma, and GABAB receptor thymic expression. Neurol Neuroimmunol Neuroinflamm. 2014 Dec; 1(4):e39. PMID: 25364773.
      Citations:    
    67. Kosmidis ML, Koutsogeorgopoulou L, Alexopoulos H, Mamali I, Vlachoyiannopoulos PG, Voulgarelis M, Moutsopoulos HM, Tzioufas AG, Dalakas MC. Reduction of Intraepidermal Nerve Fiber Density (IENFD) in the skin biopsies of patients with fibromyalgia: A controlled study. J Neurol Sci. 2014 Dec 15; 347(1-2):143-7. PMID: 25304055.
      Citations:    
    68. Dalakas MC. Pathogenesis of immune-mediated neuropathies. Biochim Biophys Acta. 2015 Apr; 1852(4):658-66. PMID: 24949885.
      Citations:    
    69. Markakis I, Alexopoulos H, Poulopoulou C, Akrivou S, Papathanasiou A, Katsiva V, Lyrakos G, Gekas G, Dalakas MC. Immunotherapy-responsive limbic encephalitis with antibodies to glutamic acid decarboxylase. J Neurol Sci. 2014 Aug 15; 343(1-2):192-4. PMID: 24950904.
      Citations:    
    70. Dalakas MC. Mechanistic Effects of IVIg in Neuroinflammatory Diseases: Conclusions Based on Clinicopathologic Correlations. J Clin Immunol. 2014 Jul; 34 Suppl 1:120-6. PMID: 24722854.
      Citations:    
    71. Davenport TE, Shrader JA, McElroy B, Rakocevic G, Dalakas M, Harris-Love MO. Validity of the single limb heel raise test to predict lower extremity disablement in patients with sporadic inclusion body myositis. Disabil Rehabil. 2014; 36(26):2270-7. PMID: 24678993.
      Citations:    
    72. Dalakas MC. IVIg in the chronic management of myasthenia gravis: Is it enough for your money? J Neurol Sci. 2014 Mar 15; 338(1-2):1-2. PMID: 24411405.
      Citations:    
    73. Harris-Love MO, Shrader JA, Davenport TE, Joe G, Rakocevic G, McElroy B, Dalakas M. Are repeated single-limb heel raises and manual muscle testing associated with peak plantar-flexor force in people with inclusion body myositis? Phys Ther. 2014 Apr; 94(4):543-52. PMID: 24309617.
      Citations:    
    74. Alexopoulos H, Dalakas MC. Immunology of stiff person syndrome and other GAD-associated neurological disorders. Expert Rev Clin Immunol. 2013 Nov; 9(11):1043-53. PMID: 24168411.
      Citations:    
    75. Alexopoulos H, Akrivou S, Dalakas MC. Glycine receptor antibodies in stiff-person syndrome and other GAD-positive CNS disorders. Neurology. 2013 Nov 26; 81(22):1962-4. PMID: 24174585.
      Citations:    
    76. Schmidt J, Dalakas MC. Inclusion body myositis: from immunopathology and degenerative mechanisms to treatment perspectives. Expert Rev Clin Immunol. 2013 Nov; 9(11):1125-33. PMID: 24138579.
      Citations:    
    77. Kosmidis ML, Alexopoulos H, Tzioufas AG, Dalakas MC. The effect of anakinra, an IL1 receptor antagonist, in patients with sporadic inclusion body myositis (sIBM): A small pilot study. J Neurol Sci. 2013 Nov 15; 334(1-2):123-5. PMID: 23998706.
      Citations:    
    78. Dalakas MC. Pathophysiology of autoimmune polyneuropathies. Presse Med. 2013 Jun; 42(6 Pt 2):e181-92. PMID: 23642299.
      Citations:    
    79. Dalakas MC. Novel future therapeutic options in Myasthenia Gravis. Autoimmun Rev. 2013 Jul; 12(9):936-41. PMID: 23537505.
      Citations:    
    80. Toro C, Olivé M, Dalakas MC, Sivakumar K, Bilbao JM, Tyndel F, Vidal N, Farrero E, Sambuughin N, Goldfarb LG. Exome sequencing identifies titin mutations causing hereditary myopathy with early respiratory failure (HMERF) in families of diverse ethnic origins. BMC Neurol. 2013; 13:29. PMID: 23514108.
      Citations:    
    81. Dalakas MC. Progress and stiff challenges in understanding the role of GAD-antibodies in stiff-person syndrome. Exp Neurol. 2013 Sep; 247:303-7. PMID: 23485793.
      Citations:    
    82. Kampylafka EI, Alexopoulos H, Kosmidis ML, Panagiotakos DB, Vlachoyiannopoulos PG, Dalakas MC, Moutsopoulos HM, Tzioufas AG. Incidence and prevalence of major central nervous system involvement in systemic lupus erythematosus: a 3-year prospective study of 370 patients. PLoS One. 2013; 8(2):e55843. PMID: 23424638.
      Citations:    
    83. Voss JG, Dobra A, Morse C, Kovacs JA, Danner RL, Munson PJ, Logan C, Rangel Z, Adelsberger JW, McLaughlin M, Adams LD, Raju R, Dalakas MC. Fatigue-Related Gene Networks Identified in CD14+ Cells Isolated From HIV-Infected Patients--Part I: Research Findings. Biol Res Nurs. 2013 Apr; 15(2):137-51. PMID: 23324479.
      Citations:    
    84. Zschüntzsch J, Voss J, Creus K, Sehmisch S, Raju R, Dalakas MC, Schmidt J. Provision of an explanation for the inefficacy of immunotherapy in sporadic inclusion body myositis: Quantitative assessment of inflammation and ß-amyloid in the muscle. Arthritis Rheum. 2012 Dec; 64(12):4094-103. PMID: 22941914.
      Citations:    
    85. Dalakas MC. Biologics and other novel approaches as new therapeutic options in myasthenia gravis: a view to the future. Ann N Y Acad Sci. 2012 Dec; 1274(1):1-8. PMID: 23252891.
      Citations:    
    86. Scott AP, Laing NG, Mastaglia F, Dalakas M, Needham M, Allcock RJ. Investigation of NOTCH4 coding region polymorphisms in sporadic inclusion body myositis. J Neuroimmunol. 2012 Sep 15; 250(1-2):66-70. PMID: 22732452.
      Citations:    
    87. Dalakas MC. Clinical trials in CIDP and chronic autoimmune demyelinating polyneuropathies. J Peripher Nerv Syst. 2012 May; 17 Suppl 2:34-9. PMID: 22548621.
      Citations:    
    88. Morse CG, Voss JG, Rakocevic G, McLaughlin M, Vinton CL, Huber C, Hu X, Yang J, Huang da W, Logun C, Danner RL, Rangel ZG, Munson PJ, Orenstein JM, Rushing EJ, Lempicki RA, Dalakas MC, Kovacs JA. HIV infection and antiretroviral therapy have divergent effects on mitochondria in adipose tissue. J Infect Dis. 2012 Jun 15; 205(12):1778-87. PMID: 22476717.
      Citations:    
    89. Schmidt J, Barthel K, Zschüntzsch J, Muth IE, Swindle EJ, Hombach A, Sehmisch S, Wrede A, Lühder F, Gold R, Dalakas MC. Nitric oxide stress in sporadic inclusion body myositis muscle fibres: inhibition of inducible nitric oxide synthase prevents interleukin-1ß-induced accumulation of ß-amyloid and cell death. Brain. 2012 Apr; 135(Pt 4):1102-14. PMID: 22436237.
      Citations:    
    90. Maurer MA, Rakocevic G, Leung CS, Quast I, Lukacišin M, Goebels N, Münz C, Wardemann H, Dalakas M, Lünemann JD. Rituximab induces sustained reduction of pathogenic B cells in patients with peripheral nervous system autoimmunity. J Clin Invest. 2012 Apr 2; 122(4):1393-402. PMID: 22426210.
      Citations:    
    91. Voss JG, Dobra A, Morse C, Kovacs JA, Raju R, Danner RL, Munson PJ, Logan C, Rangel Z, Adelsberger JW, McLaughlin M, Adams LD, Dalakas MC. Fatigue-Related Gene Networks Identified in CD14+ Cells Isolated From HIV-Infected Patients--Part II: Statistical Analysis. Biol Res Nurs. 2013 Apr; 15(2):152-9. PMID: 22084402.
      Citations:    
    92. Dalakas MC. Inflammatory myopathies: management of steroid resistance. Curr Opin Neurol. 2011 Oct; 24(5):457-62. PMID: 21799409.
      Citations:    
    93. Dalakas MC. Advances in the diagnosis, pathogenesis and treatment of CIDP. Nat Rev Neurol. 2011 Sep; 7(9):507-17. PMID: 21844897.
      Citations:    
    94. Deng C, Hanna K, Bril V, Dalakas MC, Donofrio P, van Doorn PA, Hartung HP, Merkies IS. Challenges of clinical trial design when there is lack of clinical equipoise: use of a response-conditional crossover design. J Neurol. 2012 Feb; 259(2):348-52. PMID: 21822934.
      Citations:    
    95. Latov N, Dalakas M, Vallat JM, Donofrio P, Hartung HP, Toyka KV. Biomarkers in the diagnosis and therapy of CIDP: Proceedings of the Biomarkers Faculty Meeting; June 8-9, 2010, Athens, Greece. J Peripher Nerv Syst. 2011 Jun; 16 Suppl 1:1-2. PMID: 21696489.
      Citations:    
    96. Dalakas MC. Potential biomarkers for monitoring therapeutic response in patients with CIDP. J Peripher Nerv Syst. 2011 Jun; 16 Suppl 1:63-7. PMID: 21696503.
      Citations:    
    97. Dalakas MC. Immunotherapy of inflammatory myopathies: practical approach and future prospects. Curr Treat Options Neurol. 2011 Jun; 13(3):311-23. PMID: 21365201.
      Citations:    
    98. Dalakas MC. Pathogenesis and therapies of immune-mediated myopathies. Autoimmun Rev. 2012 Jan; 11(3):203-6. PMID: 21619945.
      Citations:    
    99. Scott AP, Laing NG, Mastaglia F, Needham M, Walter MC, Dalakas MC, Allcock RJ. Recombination mapping of the susceptibility region for sporadic inclusion body myositis within the major histocompatibility complex. J Neuroimmunol. 2011 Jun; 235(1-2):77-83. PMID: 21543121.
      Citations:    
    100. Dalakas MC. Pathophysiology of inflammatory and autoimmune myopathies. Presse Med. 2011 Apr; 40(4 Pt 2):e237-47. PMID: 21411269.
      Citations:    
    101. Alexopoulos H, Kosmidis ML, Dalmau J, Dalakas MC. Paraneoplastic anti-NMDAR encephalitis: long term follow-up reveals persistent serum antibodies. J Neurol. 2011 Aug; 258(8):1568-70. PMID: 21384161.
      Citations:    
    102. Pavlakis PP, Alexopoulos H, Kosmidis ML, Stamboulis E, Routsias JG, Tzartos SJ, Tzioufas AG, Moutsopoulos HM, Dalakas MC. Peripheral neuropathies in Sjogren syndrome: a new reappraisal. J Neurol Neurosurg Psychiatry. 2011 Jul; 82(7):798-802. PMID: 21172862.
      Citations:    
    103. Bril V, Banach M, Dalakas MC, Deng C, Donofrio P, Hanna K, Hartung HP, Hughes RA, Katzberg H, Latov N, Merkies IS, Van Doorn PA. Electrophysiologic correlations with clinical outcomes in CIDP. Muscle Nerve. 2010 Oct; 42(4):492-7. PMID: 20665514.
      Citations:    
    104. Donofrio PD, Bril V, Dalakas MC, Deng C, Hanna K, Hartung HP, Hughes R, Latov N, Merkies I, van Doorn P. Safety and tolerability of immune globulin intravenous in chronic inflammatory demyelinating polyradiculoneuropathy. Arch Neurol. 2010 Sep; 67(9):1082-8. PMID: 20837852.
      Citations:    
    105. Merkies IS, Hughes RA, Donofrio P, Bril V, Dalakas MC, Hanna K, Hartung HP, Latov N, van Doorn PA, Deng C. Understanding the consequences of chronic inflammatory demyelinating polyradiculoneuropathy from impairments to activity and participation restrictions and reduced quality of life: the ICE study. J Peripher Nerv Syst. 2010 Sep; 15(3):208-15. PMID: 21040143.
      Citations:    
    106. Alexopoulos H, Dalakas MC. A critical update on the immunopathogenesis of Stiff Person Syndrome. Eur J Clin Invest. 2010 Nov; 40(11):1018-25. PMID: 20636380.
      Citations:    
    107. Latov N, Deng C, Dalakas MC, Bril V, Donofrio P, Hanna K, Hartung HP, Hughes RA, Merkies IS, van Doorn PA. Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. Arch Neurol. 2010 Jul; 67(7):802-7. PMID: 20457948.
      Citations:    
    108. Dalakas MC. Inflammatory muscle diseases: a critical review on pathogenesis and therapies. Curr Opin Pharmacol. 2010 Jun; 10(3):346-52. PMID: 20409756.
      Citations:    
    109. Schmidt J, Dalakas MC. Pathomechanisms of inflammatory myopathies: recent advances and implications for diagnosis and therapies. Expert Opin Med Diagn. 2010 May; 4(3):241-50. PMID: 23488533.
      Citations:    
    110. Dalakas MC. Pathogenesis and Treatment of Anti-MAG Neuropathy. Curr Treat Options Neurol. 2010 Mar; 12(2):71-83. PMID: 20842571.
      Citations:    
    111. Kosmidis ML, Dalakas MC. Practical considerations on the use of rituximab in autoimmune neurological disorders. Ther Adv Neurol Disord. 2010 Mar; 3(2):93-105. PMID: 21179602.
      Citations:    
    112. Dalakas MC. Immunotherapy of myositis: issues, concerns and future prospects. Nat Rev Rheumatol. 2010 Mar; 6(3):129-37. PMID: 20125096.
      Citations:    
    113. Goldfarb LG, Dalakas MC. Tragedy in a heartbeat: malfunctioning desmin causes skeletal and cardiac muscle disease. J Clin Invest. 2009 Jul; 119(7):1806-13. PMID: 19587455.
      Citations:    
    114. Dalakas MC, Rakocevic G, Schmidt J, Salajegheh M, McElroy B, Harris-Love MO, Shrader JA, Levy EW, Dambrosia J, Kampen RL, Bruno DA, Kirk AD. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain. 2009 Jun; 132(Pt 6):1536-44. PMID: 19454532.
      Citations:    
    115. Bril V, Katzberg H, Donofrio P, Banach M, Dalakas MC, Deng C, Hanna K, Hartung HP, Hughes RA, Latov N, Merkies IS, van Doorn PA. Electrophysiology in chronic inflammatory demyelinating polyneuropathy with IGIV. Muscle Nerve. 2009 Apr; 39(4):448-55. PMID: 19260050.
      Citations:    
    116. Dalakas MC, Rakocevic G, Salajegheh M, Dambrosia JM, Hahn AF, Raju R, McElroy B. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Ann Neurol. 2009 Mar; 65(3):286-93. PMID: 19334068.
      Citations:    
    117. Dalakas MC. Stiff person syndrome: advances in pathogenesis and therapeutic interventions. Curr Treat Options Neurol. 2009 Mar; 11(2):102-10. PMID: 19210912.
      Citations:    
    118. Shatunov A, Olivé M, Odgerel Z, Stadelmann-Nessler C, Irlbacher K, van Landeghem F, Bayarsaikhan M, Lee HS, Goudeau B, Chinnery PF, Straub V, Hilton-Jones D, Damian MS, Kaminska A, Vicart P, Bushby K, Dalakas MC, Sambuughin N, Ferrer I, Goebel HH, Goldfarb LG. In-frame deletion in the seventh immunoglobulin-like repeat of filamin C in a family with myofibrillar myopathy. Eur J Hum Genet. 2009 May; 17(5):656-63. PMID: 19050726.
      Citations:    
    119. Dalakas MC. Therapeutic advances and future prospects in immune-mediated inflammatory myopathies. Ther Adv Neurol Disord. 2008 Nov; 1(3):157-66. PMID: 21180574.
      Citations:    
    120. Dalakas MC. B cells as therapeutic targets in autoimmune neurological disorders. Nat Clin Pract Neurol. 2008 Oct; 4(10):557-67. PMID: 18813230.
      Citations:    
    121. Dalakas MC, Smith SA. A "nema" of hope in the treatment of late-onset nemaline myopathy. Neurology. 2008 Aug 12; 71(7):472-3. PMID: 18695157.
      Citations:    
    122. Dalakas MC. Interplay between inflammation and degeneration: using inclusion body myositis to study "neuroinflammation". Ann Neurol. 2008 Jul; 64(1):1-3. PMID: 18626972.
      Citations:    
    123. Dalakas M. IVIg in other autoimmune neurological disorders: current status and future prospects. J Neurol. 2008 Jul; 255 Suppl 3:12-6. PMID: 18685921.
      Citations:    
    124. Dalakas MC. Invited article: inhibition of B cell functions: implications for neurology. Neurology. 2008 Jun 3; 70(23):2252-60. PMID: 18519875.
      Citations:    
    125. Schmidt J, Barthel K, Wrede A, Salajegheh M, Bähr M, Dalakas MC. Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle. Brain. 2008 May; 131(Pt 5):1228-40. PMID: 18420712.
      Citations:    
    126. Voss JG, Raju R, Logun C, Danner RL, Munson PJ, Rangel Z, Dalakas MC. A focused microarray to study human mitochondrial and nuclear gene expression. Biol Res Nurs. 2008 Apr; 9(4):272-9. PMID: 18398222.
      Citations:    
    127. Hughes RA, Donofrio P, Bril V, Dalakas MC, Deng C, Hanna K, Hartung HP, Latov N, Merkies IS, van Doorn PA. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol. 2008 Feb; 7(2):136-44. PMID: 18178525.
      Citations:    
    128. Dalakas MC. Advances in the pathogenesis and treatment of patients with stiff person syndrome. Curr Neurol Neurosci Rep. 2008 Jan; 8(1):48-55. PMID: 18367039.
      Citations:    
    129. Burbelo PD, Groot S, Dalakas MC, Iadarola MJ. High definition profiling of autoantibodies to glutamic acid decarboxylases GAD65/GAD67 in stiff-person syndrome. Biochem Biophys Res Commun. 2008 Feb 1; 366(1):1-7. PMID: 18047830.
      Citations:    
    130. Dalakas MC. Advances in the immunobiology and treatment of inflammatory myopathies. Curr Rheumatol Rep. 2007 Aug; 9(4):291-7. PMID: 17688838.
      Citations:    
    131. Lünemann JD, Schmidt J, Dalakas MC, Münz C. Macroautophagy as a pathomechanism in sporadic inclusion body myositis. Autophagy. 2007 Jul-Aug; 3(4):384-6. PMID: 17438365.
      Citations:    
    132. Salajegheh M, Raju R, Schmidt J, Dalakas MC. Upregulation of thrombospondin-1(TSP-1) and its binding partners, CD36 and CD47, in sporadic inclusion body myositis. J Neuroimmunol. 2007 Jul; 187(1-2):166-74. PMID: 17572512.
      Citations:    
    133. Dalakas MC, Rakocevic G, Shatunov A, Goldfarb L, Raju R, Salajegheh M. Inclusion body myositis with human immunodeficiency virus infection: four cases with clonal expansion of viral-specific T cells. Ann Neurol. 2007 May; 61(5):466-75. PMID: 17366634.
      Citations:    
    134. Lünemann JD, Schmidt J, Schmid D, Barthel K, Wrede A, Dalakas MC, Münz C. Beta-amyloid is a substrate of autophagy in sporadic inclusion body myositis. Ann Neurol. 2007 May; 61(5):476-83. PMID: 17469125.
      Citations:    
    135. Raju R, Dalakas MC. Absence of upregulated genes associated with protein accumulations in desmin myopathy. Muscle Nerve. 2007 Mar; 35(3):386-8. PMID: 17068785.
      Citations:    
    136. Mavragani CP, Patronas N, Dalakas M, Moutsopoulos HM. Ill-defined neurological syndromes with autoimmune background: a diagnostic challenge. J Rheumatol. 2007 Feb; 34(2):341-5. PMID: 17304657.
      Citations:    
    137. Lupu VD, Mora CA, Dambrosia J, Meer J, Dalakas M, Floeter MK. Terminal latency index in neuropathy with antibodies against myelin-associated glycoproteins. Muscle Nerve. 2007 Feb; 35(2):196-202. PMID: 17068765.
      Citations:    
    138. Sparks S, Rakocevic G, Joe G, Manoli I, Shrader J, Harris-Love M, Sonies B, Ciccone C, Dorward H, Krasnewich D, Huizing M, Dalakas MC, Gahl WA. Intravenous immune globulin in hereditary inclusion body myopathy: a pilot study. BMC Neurol. 2007; 7:3. PMID: 17261181.
      Citations:    
    139. Gold R, Stangel M, Dalakas MC. Drug Insight: the use of intravenous immunoglobulin in neurology--therapeutic considerations and practical issues. Nat Clin Pract Neurol. 2007 Jan; 3(1):36-44. PMID: 17205073.
      Citations:    
    140. Dalakas MC. Autoimmune inflammatory myopathies. Handb Clin Neurol. 2007; 86:273-301. PMID: 18809006.
      Citations:    
    141. Rakocevic G, Raju R, Semino-Mora C, Dalakas MC. Stiff person syndrome with cerebellar disease and high-titer anti-GAD antibodies. Neurology. 2006 Sep 26; 67(6):1068-70. PMID: 17000981.
      Citations:    
    142. Salajegheh M, Bryan WW, Dalakas MC. The challenge of diagnosing ALS in patients with prior poliomyelitis. Neurology. 2006 Sep 26; 67(6):1078-9. PMID: 17000983.
      Citations:    
    143. Raju R, Rakocevic G, Chen Z, Hoehn G, Semino-Mora C, Shi W, Olsen R, Dalakas MC. Autoimmunity to GABAA-receptor-associated protein in stiff-person syndrome. Brain. 2006 Dec; 129(Pt 12):3270-6. PMID: 16984900.
      Citations:    
    144. Dalakas MC. Role of IVIg in autoimmune, neuroinflammatory and neurodegenerative disorders of the central nervous system: present and future prospects. J Neurol. 2006 Sep; 253 Suppl 5:V25-32. PMID: 16998751.
      Citations:    
    145. Goudeau B, Rodrigues-Lima F, Fischer D, Casteras-Simon M, Sambuughin N, de Visser M, Laforet P, Ferrer X, Chapon F, Sjöberg G, Kostareva A, Sejersen T, Dalakas MC, Goldfarb LG, Vicart P. Variable pathogenic potentials of mutations located in the desmin alpha-helical domain. Hum Mutat. 2006 Sep; 27(9):906-13. PMID: 16865695.
      Citations:    
    146. Vasconcelos OM, Prokhorenko OA, Kelley KF, Vo AH, Olsen CH, Dalakas MC, Halstead LS, Jabbari B, Campbell WW. A comparison of fatigue scales in postpoliomyelitis syndrome. Arch Phys Med Rehabil. 2006 Sep; 87(9):1213-7. PMID: 16935057.
      Citations:    
    147. Dalakas MC. Sporadic inclusion body myositis--diagnosis, pathogenesis and therapeutic strategies. Nat Clin Pract Neurol. 2006 Aug; 2(8):437-47. PMID: 16932602.
      Citations:    
    148. Dalakas MC. B cells in the pathophysiology of autoimmune neurological disorders: a credible therapeutic target. Pharmacol Ther. 2006 Oct; 112(1):57-70. PMID: 16644016.
      Citations:    
    149. Dalakas MC. Mechanisms of disease: signaling pathways and immunobiology of inflammatory myopathies. Nat Clin Pract Rheumatol. 2006 Apr; 2(4):219-27. PMID: 16932688.
      Citations:    
    150. Dalakas MC. Therapeutic targets in patients with inflammatory myopathies: present approaches and a look to the future. Neuromuscul Disord. 2006 Apr; 16(4):223-36. PMID: 16542836.
      Citations:    
    151. Latov N, Gorson KC, Brannagan TH, Freeman RL, Apostolski S, Berger AR, Bradley WG, Briani C, Bril V, Busis NA, Cros DP, Dalakas MC, Donofrio PD, Dyck PJ, England JD, Fisher MA, Herrmann DN, Menkes DL, Sahenk Z, Sander HW, Triggs WJ, Vallat JM. Diagnosis and Treatment of Chronic Immune-mediated Neuropathies. J Clin Neuromuscul Dis. 2006 Mar; 7(3):141-57. PMID: 19078800.
      Citations:    
    152. Dalakas MC. Inflammatory, immune, and viral aspects of inclusion-body myositis. Neurology. 2006 Jan 24; 66(2 Suppl 1):S33-8. PMID: 16432143.
      Citations:    
    153. Dalakas MC. The role of high-dose immune globulin intravenous in the treatment of dermatomyositis. Int Immunopharmacol. 2006 Apr; 6(4):550-6. PMID: 16504918.
      Citations:    
    154. Raju R, Foote J, Banga JP, Hall TR, Padoa CJ, Dalakas MC, Ortqvist E, Hampe CS. Analysis of GAD65 autoantibodies in Stiff-Person syndrome patients. J Immunol. 2005 Dec 1; 175(11):7755-62. PMID: 16301686.
      Citations:    
    155. Dalakas MC. Intravenous immunoglobulin in patients with anti-GAD antibody-associated neurological diseases and patients with inflammatory myopathies: effects on clinicopathological features and immunoregulatory genes. Clin Rev Allergy Immunol. 2005 Dec; 29(3):255-69. PMID: 16391401.
      Citations:    
    156. Schreiner B, Voss J, Wischhusen J, Dombrowski Y, Steinle A, Lochmüller H, Dalakas M, Melms A, Wiendl H. Expression of toll-like receptors by human muscle cells in vitro and in vivo: TLR3 is highly expressed in inflammatory and HIV myopathies, mediates IL-8 release and up-regulation of NKG2D-ligands. FASEB J. 2006 Jan; 20(1):118-20. PMID: 16293707.
      Citations:    
    157. Gottlieb E, Ciccone C, Darvish D, Naiem-Cohen S, Dalakas MC, Savelkoul PJ, Krasnewich DM, Gahl WA, Huizing M. Single nucleotide polymorphisms in the dystroglycan gene do not correlate with disease severity in hereditary inclusion body myopathy. Mol Genet Metab. 2005 Sep-Oct; 86(1-2):244-9. PMID: 16112887.
      Citations:    
    158. Sivakumar K, Kyriakides T, Puls I, Nicholson GA, Funalot B, Antonellis A, Sambuughin N, Christodoulou K, Beggs JL, Zamba-Papanicolaou E, Ionasescu V, Dalakas MC, Green ED, Fischbeck KH, Goldfarb LG. Phenotypic spectrum of disorders associated with glycyl-tRNA synthetase mutations. Brain. 2005 Oct; 128(Pt 10):2304-14. PMID: 16014653.
      Citations:    
    159. Sparks SE, Ciccone C, Lalor M, Orvisky E, Klootwijk R, Savelkoul PJ, Dalakas MC, Krasnewich DM, Gahl WA, Huizing M. Use of a cell-free system to determine UDP-N-acetylglucosamine 2-epimerase and N-acetylmannosamine kinase activities in human hereditary inclusion body myopathy. Glycobiology. 2005 Nov; 15(11):1102-10. PMID: 15987957.
      Citations:    
    160. Ameli R, Snow J, Rakocevic G, Dalakas MC. A neuropsychological assessment of phobias in patients with stiff person syndrome. Neurology. 2005 Jun 14; 64(11):1961-3. PMID: 15955955.
      Citations:    
    161. Levy LM, Levy-Reis I, Fujii M, Dalakas MC. Brain gamma-aminobutyric acid changes in stiff-person syndrome. Arch Neurol. 2005 Jun; 62(6):970-4. PMID: 15956168.
      Citations:    
    162. Dalakas MC. The role of IVIg in the treatment of patients with stiff person syndrome and other neurological diseases associated with anti-GAD antibodies. J Neurol. 2005 May; 252 Suppl 1:I19-25. PMID: 15959668.
      Citations:    
    163. Raju R, Dalakas MC. Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes. Brain. 2005 Aug; 128(Pt 8):1887-96. PMID: 15857930.
      Citations:    
    164. Renaud S, Hays AP, Brannagan TH, Sander HW, Edgar M, Weimer LH, Olarte MR, Dalakas MC, Xiang Z, Danon MJ, Latov N. Gene expression profiling in chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol. 2005 Feb; 159(1-2):203-14. PMID: 15652421.
      Citations:    
    165. Dalakas MC. Inhibiting leukocyte recruitment to the brain by IVIg: is it relevant to the treatment of demyelinating CNS disorders? Brain. 2004 Dec; 127(Pt 12):2569-71. PMID: 15561895.
      Citations:    
    166. Dalakas MC. Inflammatory disorders of muscle: progress in polymyositis, dermatomyositis and inclusion body myositis. Curr Opin Neurol. 2004 Oct; 17(5):561-7. PMID: 15367860.
      Citations:    
    167. Dalakas MC. From canine to man: on antibodies, macrophages, and dendritic cells in inflammatory myopathies. Muscle Nerve. 2004 Jun; 29(6):753-5. PMID: 15170607.
      Citations:    
    168. Rakocevic G, Raju R, Dalakas MC. Anti-glutamic acid decarboxylase antibodies in the serum and cerebrospinal fluid of patients with stiff-person syndrome: correlation with clinical severity. Arch Neurol. 2004 Jun; 61(6):902-4. PMID: 15210528.
      Citations:    
    169. Dalakas MC. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacol Ther. 2004 Jun; 102(3):177-93. PMID: 15246245.
      Citations:    
    170. Dalakas MC. The future prospects in the classification, diagnosis and therapies of inflammatory myopathies: a view to the future from the "bench-to-bedside". J Neurol. 2004 Jun; 251(6):651-7. PMID: 15311338.
      Citations:    
    171. Dalakas MC. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA. 2004 May 19; 291(19):2367-75. PMID: 15150209.
      Citations:    
    172. Schmidt J, Rakocevic G, Raju R, Dalakas MC. Upregulated inducible co-stimulator (ICOS) and ICOS-ligand in inclusion body myositis muscle: significance for CD8+ T cell cytotoxicity. Brain. 2004 May; 127(Pt 5):1182-90. PMID: 15047591.
      Citations:    
    173. Huizing M, Rakocevic G, Sparks SE, Mamali I, Shatunov A, Goldfarb L, Krasnewich D, Gahl WA, Dalakas MC. Hypoglycosylation of alpha-dystroglycan in patients with hereditary IBM due to GNE mutations. Mol Genet Metab. 2004 Mar; 81(3):196-202. PMID: 14972325.
      Citations:    
    174. Dagvadorj A, Olivé M, Urtizberea JA, Halle M, Shatunov A, Bönnemann C, Park KY, Goebel HH, Ferrer I, Vicart P, Dalakas MC, Goldfarb LG. A series of West European patients with severe cardiac and skeletal myopathy associated with a de novo R406W mutation in desmin. J Neurol. 2004 Feb; 251(2):143-9. PMID: 14991347.
      Citations:    
    175. Dalakas MC. Molecular pathogenesis of inflammatory myopathies and future therapeutic strategies. Suppl Clin Neurophysiol. 2004; 57:288-303. PMID: 16106627.
      Citations:    
    176. Berger AR, Bradley WG, Brannagan TH, Busis NA, Cros DP, Dalakas MC, Danon MJ, Donofrio P, Engel WK, England JD, Feldman EL, Freeman RL, Kinsella LJ, Lacomis D, Latov N, Menkes DL, Sander HW, Thomas FP, Triggs WJ, Windebank AJ, Wolfe GI. Guidelines for the diagnosis and treatment of chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst. 2003 Dec; 8(4):282-4. PMID: 14641652.
      Citations:    
    177. Kaminska A, Strelkov SV, Goudeau B, Olivé M, Dagvadorj A, Fidzianska A, Simon-Casteras M, Shatunov A, Dalakas MC, Ferrer I, Kwiecinski H, Vicart P, Goldfarb LG. Small deletions disturb desmin architecture leading to breakdown of muscle cells and development of skeletal or cardioskeletal myopathy. Hum Genet. 2004 Feb; 114(3):306-13. PMID: 14648196.
      Citations:    
    178. McCrone P, Chisholm D, Knapp M, Hughes R, Comi G, Dalakas MC, Illa I, Kilindireas C, Nobile-Orazio E, Swan A, Van den Bergh P, Willison HJ. Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol. 2003 Nov; 10(6):687-94. PMID: 14641514.
      Citations:    
    179. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003 Sep 20; 362(9388):971-82. PMID: 14511932.
      Citations:    
    180. Raju R, Vasconcelos O, Granger R, Dalakas MC. Expression of IFN-gamma-inducible chemokines in inclusion body myositis. J Neuroimmunol. 2003 Aug; 141(1-2):125-31. PMID: 12965263.
      Citations:    
    181. Ho NC, Sandusky S, Madike V, Francomano CA, Dalakas MC. Clinico-pathogenetic findings and management of chondrodystrophic myotonia (Schwartz-Jampel syndrome): a case report. BMC Neurol. 2003 Jul 2; 3:3. PMID: 12839625.
      Citations:    
    182. Dalakas MC, Clark WM. Strokes, thromboembolic events, and IVIg: rare incidents blemish an excellent safety record. Neurology. 2003 Jun 10; 60(11):1736-7. PMID: 12796522.
      Citations:    
    183. Hohlfeld R, Dalakas MC. Basic principles of immunotherapy for neurologic diseases. Semin Neurol. 2003 Jun; 23(2):121-32. PMID: 12894378.
      Citations:    
    184. Dalakas MC. Therapeutic approaches in patients with inflammatory myopathies. Semin Neurol. 2003 Jun; 23(2):199-206. PMID: 12894385.
      Citations:    
    185. Dalakas MC, Dagvadorj A, Goudeau B, Park KY, Takeda K, Simon-Casteras M, Vasconcelos O, Sambuughin N, Shatunov A, Nagle JW, Sivakumar K, Vicart P, Goldfarb LG. Progressive skeletal myopathy, a phenotypic variant of desmin myopathy associated with desmin mutations. Neuromuscul Disord. 2003 Mar; 13(3):252-8. PMID: 12609507.
      Citations:    
    186. Gold R, Dalakas MC, Toyka KV. Immunotherapy in autoimmune neuromuscular disorders. Lancet Neurol. 2003 Jan; 2(1):22-32. PMID: 12849298.
      Citations:    
    187. Vasconcelos OM, Dalakas MC. Stiff-person Syndrome. Curr Treat Options Neurol. 2003 Jan; 5(1):79-90. PMID: 12521565.
      Citations:    
    188. Kieseier BC, Dalakas MC, Hartung HP. Immune mechanisms in chronic inflammatory demyelinating neuropathy. Neurology. 2002 Dec 24; 59(12 Suppl 6):S7-12. PMID: 12499465.
      Citations:    
    189. Dalakas MC. Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology. 2002 Dec 24; 59(12 Suppl 6):S13-21. PMID: 12499466.
      Citations:    
    190. Dalakas MC. Pro-inflammatory cytokines and motor neuron dysfunction: is there a connection in post-polio syndrome? J Neurol Sci. 2002 Dec 15; 205(1):5-8. PMID: 12409176.
      Citations:    
    191. Vasconcelos OM, Raju R, Dalakas MC. GNE mutations in an American family with quadriceps-sparing IBM and lack of mutations in s-IBM. Neurology. 2002 Dec 10; 59(11):1776-9. PMID: 12473769.
      Citations:    
    192. Dalakas MC. Muscle biopsy findings in inflammatory myopathies. Rheum Dis Clin North Am. 2002 Nov; 28(4):779-98, vi. PMID: 12506772.
      Citations:    
    193. Dalakas MC. Blockade of blocking antibodies in Guillain-Barré syndromes: "unblocking" the mystery of action of intravenous immunoglobulin. Ann Neurol. 2002 Jun; 51(6):667-9. PMID: 12112069.
      Citations:    
    194. Arikawa-Hirasawa E, Le AH, Nishino I, Nonaka I, Ho NC, Francomano CA, Govindraj P, Hassell JR, Devaney JM, Spranger J, Stevenson RE, Iannaccone S, Dalakas MC, Yamada Y. Structural and functional mutations of the perlecan gene cause Schwartz-Jampel syndrome, with myotonic myopathy and chondrodysplasia. Am J Hum Genet. 2002 May; 70(5):1368-75. PMID: 11941538.
      Citations:    
    195. Dalakas MC. Inflammatory myopathies. Recent advances in pathogenesis and therapy. Adv Neurol. 2002; 88:253-71. PMID: 11908230.
      Citations:    
    Dalakas's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (451)
    Explore
    _
    Co-Authors (3)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _